

Olga Ochoa-Gondar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5752959/publications.pdf>

Version: 2024-02-01

35
papers

1,272
citations

489802

18
h-index

406436

35
g-index

43
all docs

43
docs citations

43
times ranked

1431
citing authors

#	ARTICLE	IF	CITATIONS
1	Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain. <i>Medicina Clínica</i> , 2022, 158, 251-259.	0.3	7
2	Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 251-259.	0.1	1
3	Development of a predictive prognostic rule for early assessment of COVID-19 patients in primary care settings. <i>Atencion Primaria</i> , 2021, 53, 102118.	0.6	10
4	COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population-based cohort study in Southern Catalonia, Spain, March-June 2020. <i>BMC Public Health</i> , 2021, 21, 1795.	1.2	16
5	Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016. <i>Vaccine</i> , 2020, 38, 1170-1180.	1.7	11
6	Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1379-1388.	1.0	35
7	Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. <i>BMJ Open</i> , 2020, 10, e041577.	0.8	29
8	Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. <i>Eurosurveillance</i> , 2019, 24, .	3.9	22
9	Incidence and mortality of myocardial infarction among Catalanian older adults with and without underlying risk conditions: The CAPAMIS study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1822-1830.	0.8	16
10	Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 196.	1.3	18
11	Pneumococcal pneumonia in adults 60 years or older: Incidence, mortality and prevention. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 199-202.	0.1	0
12	Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2953-2958.	1.4	20
13	Pneumococcal pneumonia in adults 60 years or older: Incidence, mortality and prevention. <i>Medicina Clínica</i> , 2016, 146, 199-202.	0.3	9
14	Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. <i>Infection</i> , 2015, 43, 699-706.	2.3	20
15	Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 909-917.	2.9	129
16	Pneumococcal conjugate vaccination: correlates of protection. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 784-786.	4.6	11
17	Evaluating Clinical Effectiveness of Pneumococcal Vaccination in Preventing Stroke: The CAPAMIS Study, 3-Year Follow-up. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 1577-1584.	0.7	19
18	Preventing Pneumococcal Disease in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 263-276.	1.3	46

#	ARTICLE	IF	CITATIONS
19	Ineffectiveness of Pneumococcal Vaccination in Cardiovascular Prevention: The CAPAMIS Study. <i>JAMA Internal Medicine</i> , 2013, 173, 1.	2.6	17
20	Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 363-370.	1.4	30
21	Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 639-644.	1.4	14
22	Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview. <i>Expert Review of Vaccines</i> , 2012, 11, 221-236.	2.0	15
23	Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. <i>BMC Public Health</i> , 2012, 12, 222.	1.2	41
24	Invasive pneumococcal disease in Catalanian elderly people, 2002-2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era. <i>Vaccine</i> , 2011, 29, 7430-7434.	1.7	9
25	Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002-2009: An increase in serotypes not contained in the heptavalent conjugate vaccine. <i>Journal of Infection</i> , 2011, 63, 434-440.	1.7	9
26	Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. <i>BMC Public Health</i> , 2010, 10, 25.	1.2	26
27	Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. <i>BMC Infectious Diseases</i> , 2010, 10, 73.	1.3	71
28	Drug-resistance in <i>Streptococcus pneumoniae</i> isolates among Spanish middle aged and older adults with community-acquired pneumonia. <i>BMC Infectious Diseases</i> , 2009, 9, 36.	1.3	17
29	Epidemiology of community-acquired pneumonia in older adults: A population-based study. <i>Respiratory Medicine</i> , 2009, 103, 309-316.	1.3	164
30	Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case-control study. <i>Vaccine</i> , 2009, 27, 1504-1510.	1.7	82
31	The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 Study. <i>BMC Public Health</i> , 2008, 8, 222.	1.2	85
32	Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: Results of the EVAN-65 study. <i>Vaccine</i> , 2008, 26, 1955-1962.	1.7	35
33	Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalanian older adults: 4-years follow-up. <i>BMC Public Health</i> , 2006, 6, 231.	1.2	28
34	Protective Effects of the 23-valent Pneumococcal Polysaccharide Vaccine in the Elderly Population: The EVAN-65 Study. <i>Clinical Infectious Diseases</i> , 2006, 43, 860-868.	2.9	180
35	Antipneumococcal Vaccination in COPD Patients. , 0, , .		0